News and Announcements
Actinogen Obtains FDA Approval to Commence Alzheimer’s Disease Clinical Trial
- Published February 07, 2017 9:19AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical announced today (3/01/17) that the US Food and Drug Administration (FDA) has approved their Investigational New Drug (IND) application to recruit for the XanADu, Phase II for the clinical trial of Xanamem™ which will target patients with mild Alzheimer’s disease, in the US.
The trail is tilted: XanADu: A Phase II Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to assess the safety, tolerability and efficacy of Xanamem™ in subjects with mild dementia. XanADu will enrol 174 patients at clinical sites across the USA, the UK and Australia. The trail is registered on www.clinicaltrials.gov.
The IND approval follows an extensive in-depth review by the FDA of past research and clinical data on Xanamem™ and of Phase II of the XanADu clinical trial. This IND approval provides strong endorsement by the FDA for Xanamem™ development in Alzheimer’s disease. Xanamem™ is different from the existing products on the market for Alzheimer’s disease. Xanamem™ has been specifically designed to block excess production of cortisol (the stress hormone), in the areas of the brain most affected by Alzheimer’s disease. The idea of raised cortisol has been strongly associated with Alzheimer’s disease, and with research has now become an important target for treating the disease.
Dr Bill Ketelbey, CEO of Actinogen Medical said: “We are delighted with the IND approval as it represents a major milestone for Actinogen Medical in the development of Xanamem™ in the treatment of Alzheimer’s disease. New treatment options are desperately needed for Alzheimer’s disease and this IND approval is a significant step forward in demonstrating that Xanamem™ is an effective treatment option for this devastating disease.”
Actinogen is currently awaiting to receive similar approvals from authorities in Australia and the UK within the next two months, and for the trail to begin actively recruiting patients by Q2, 2017.
XanADu, is currently the largest global Alzheimer’s disease study conducted by an Australian biotech company. Nearly half planned sites have been scheduled for the US and will represent around 50% of the market for Alzheimer’s medication.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
